L&K BIOMED CO., LTD. Q3 profit from main business KRW 0.9 billion, up 156.6% from a year earlier; sales KRW 12.2 billion
AI summary · Not investment advice
L&K Biomed sold KRW 12.2 billion in Q3 and earned KRW 0.9 billion from its main business, up 156.6% from a year earlier and down 31.9% from the previous quarter.
Operating profit · 3 months
KRW 867.9 million
Key facts
- Revenue (3 months)
- KRW 12.2 billion
- Net income (3 months)
- KRW -11.0 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 10.1 billion
- Revenue (year to date)
- KRW 33.5 billion
- Operating profit (prior-year 3 months)
- KRW 338.3 million
- Operating profit (year to date)
- KRW 2.2 billion
- Net income (prior-year 3 months)
- KRW 2.6 billion
- Net income (year to date)
- KRW 4.9 billion
Commentary
AI commentary · Not investment advice
What happened
L&K Biosciences reported its 3rd-quarter results on a consolidated basis. Sales for the 3 months were KRW 12.24 billion, and operating profit (profit from its main business) was KRW 868 million.
In the company's terms
Sales for the 3 months rose 21.2% from the same period a year earlier. They rose 4.3% from the previous quarter.
What changes for shareholders
Operating profit for the 3 months rose 156.6% from a year earlier. It fell 31.9% from the previous quarter.
Net income (final profit after all costs) for the 3 months was a loss of KRW 11.05 billion. The previous quarter showed a profit, so this is a swing to a loss. A year earlier, the 3 months showed net income of KRW 2.58 billion.
For the year to date, sales were KRW 33.47 billion. Operating profit was KRW 2.25 billion. Net income was KRW 4.86 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
L